These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11272061)

  • 1. [Liver function tests during administration of triphasic contraceptives containing Norgestimate].
    Paseka J; Unzeitig V; Cibula D; Chroust K
    Ceska Gynekol; 2000 Nov; 65(6):420-4. PubMed ID: 11272061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of the effect of a triphasic contraceptive agent with norgestimate on acne].
    Cibula D; Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K
    Ceska Gynekol; 2000 Mar; 65(2):79-82. PubMed ID: 10953475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].
    Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K; Cibula D
    Ceska Gynekol; 1999 Jul; 64(4):246-54. PubMed ID: 10568064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.
    Warren MP; Miller KK; Olson WH; Grinspoon SK; Friedman AJ
    Contraception; 2005 Sep; 72(3):206-11. PubMed ID: 16102557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.
    Hampton RM; Zhang HF; Barnowski C; Wan GJ
    Contraception; 2008 Jun; 77(6):415-9. PubMed ID: 18477490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on blood lipid and androgen levels of two triphasic oral contraceptives.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():114-6. PubMed ID: 8260968
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate.
    Burkman RT; Kafrissen ME; Olson W; Osterman J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():5-8. PubMed ID: 1324556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
    Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
    [No Abstract]   [Full Text] [Related]  

  • 17. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
    Rubio-Lotvin B; Gonzales-Ansorena R
    Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norgestimate: overview of a monophasic formulation.
    Anderson FD; Gillmer MD
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.